We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+15.18%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.32B
AUM Growth
+$87.8M
Cap. Flow
+$6.46M
Cap. Flow %
0.49%
Top 10 Hldgs %
27.55%
Holding
138
New
17
Increased
50
Reduced
27
Closed
18

Top Buys

Rank Stock Value
1
BXLT
BAXALTA INC COM STK (DE)
BXLT
+$28.2M
2
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$22.2M
3
WCG
Wellcare Health Plans, Inc.
WCG
+$17.8M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$17.5M
5
AGN
Allergan plc
AGN
+$10.7M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$38M
2
STJ
St Jude Medical
STJ
+$33.4M
3
TMH
Team Health Holdings Inc
TMH
+$17M
4
ADPT
Adeptus Health Inc
ADPT
+$14.4M
5
TRNX
TORNIER N V SHARES (NLD)
TRNX
+$13.5M

Sector Composition

Rank Sector Weight
1 Healthcare 77%
2 Financials 3.37%
3 Industrials 0.48%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EGLT
101
DELISTED
Egalet Corporation
EGLT
$3.31M 0.25%
300,000
– –
DMTX
102
DELISTED
Dimension Therapeutics, Inc
DMTX
$3.06M 0.23%
+271,370
New +$3.43M
OREX
103
DELISTED
Orexigen Therapeutics, Inc.
OREX
$2.84M 0.22%
165,000
– –
ASMB icon
104
Assembly Biosciences
ASMB
$529M
$2.79M 0.21%
30,917
– –
GNCA
105
DELISTED
Genocea Biosciences, Inc.
GNCA
$2.53M 0.19%
60,000
-21,250
-26% -$1.01M
ICPT
106
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$2.31M 0.18%
15,500
-17,000
-52% -$2.88M
GBT
107
DELISTED
Global Blood Therapeutics, Inc.
GBT
$2.28M 0.17%
70,500
+10,500
+18% +$455K
NBRV
108
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$2.24M 0.17%
940
-358
-28% -$873K
SRPT icon
109
CALL
Sarepta Therapeutics
SRPT
$1.77B
$2.06M 0.16%
+53,300
New +$1.73M
TTPH
110
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$2.01M 0.15%
+10,000
New +$2M
ANTH
111
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$1.76M 0.13%
47,500
-2,500
-5% -$110K
DARE icon
112
Dare Bioscience
DARE
$21M
$1.75M 0.13%
5,208
– –
INFI
113
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1.69M 0.13%
215,000
– –
BLUE
114
DELISTED
bluebird bio
BLUE
$1.28M 0.1%
1,544
-1,930
-56% -$1.93M
SPHS
115
DELISTED
Sophiris Bio, Inc.
SPHS
$1.14M 0.09%
+628,563
New +$930K
SYBX
116
DELISTED
Synlogic
SYBX
$938K 0.07%
+1,429
New +$947K
DBVT
117
DBV Technologies
DBVT
$847M
$908K 0.07%
2,500
– –
PBYI icon
118
Puma Biotechnology
PBYI
$454M
$862K 0.07%
11,000
-4,900
-31% -$385K
PRTK
119
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$585K 0.04%
+30,827
New +$588K
PETX
120
DELISTED
Aratana Therapeutics, Inc.
PETX
$242K 0.02%
43,445
-441,555
-91% -$2.92M
CVS icon
121
CVS Health
CVS
$122B
– –
-120,000
Closed -$11.6M
DVA icon
122
DaVita
DVA
$11.7B
– –
-122,050
Closed -$8.83M
PTCT icon
123
PTC Therapeutics
PTCT
$6.12B
– –
-42,960
Closed -$1.15M
ALBO
124
DELISTED
Albireo Pharma Inc
ALBO
– –
-133,333
Closed -$1.76M
CSLT
125
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
– –
-1,000,000
Closed -$4.2M
2 3 4
5
6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2015 Portfolio in Review

As of Q4 2015, Rock Springs Capital Management held 138 positions worth $1.32B, up 7.1% from $1.23B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Rock Springs Capital Management's Q4 2015 filing shows 17 new, 50 increased, 27 reduced and 18 closed positions. Its largest new stake was BAXALTA INC COM STK (DE): 810,000 shares worth $31.6M. The largest sale was AbbVie, an estimated $38M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 76% a quarter earlier, followed by Financials and Industrials.

  • Rock Springs Capital Management's largest Q4 2015 buy was BAXALTA INC COM STK (DE): 810,000 shares worth $31.6M.
  • Rock Springs Capital Management added most to Allergan plc in Q4 2015, an estimated $10.7M increase.
  • Rock Springs Capital Management's biggest Q4 2015 reduction was AbbVie, cutting an estimated $38M.
  • Rock Springs Capital Management fully exited St Jude Medical in Q4 2015, selling an estimated $33.4M.
  • Rock Springs Capital Management's ten largest holdings make up 28% of its $1.32B portfolio in Q4 2015.
  • Rock Springs Capital Management opened 17 new positions and closed 18 in Q4 2015.
  • Rock Springs Capital Management's portfolio value rose 7.1% quarter-over-quarter to $1.32B.

Based on Rock Springs Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.